SecSonar.com

Beam Therapeutics Inc. (BEAM)

Beam Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Beam Therapeutics Inc. (BEAM) is a Biotechnology company based in US with a market capitalization of $3.4B. Revenue grew 120.0% year-over-year and free cash flow was negative at -$360M. This page tracks BEAM's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 393 employees · IPO Feb 6, 2020

Valuation

Valuation & price

$27.93 · as of May 17, 2026 · -21.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.78

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$35.53$25.77$16.01Jul 25Dec 25Jul 26Jul 7, 25$19.18Jul 9, 25$21.46Jul 11, 25$21.16Jul 15, 25$19.58Jul 17, 25$20.45Jul 21, 25$21.03Jul 23, 25$22.16Jul 25, 25$21.72Jul 29, 25$19.93Jul 31, 25$19.71Aug 4, 25$19.12Aug 6, 25$18.30Aug 11, 25$17.17Aug 13, 25$17.52Aug 15, 25$17.82Aug 19, 25$16.35Aug 21, 25$16.01Aug 25, 25$16.44Aug 27, 25$16.86Aug 29, 25$16.36Sep 3, 25$18.76Sep 5, 25$20.88Sep 9, 25$20.36Sep 11, 25$21.55Sep 16, 25$22.91Sep 18, 25$25.10Sep 22, 25$24.41Sep 24, 25$23.59Sep 26, 25$22.97Sep 30, 25$24.27Oct 2, 25$25.59Oct 6, 25$25.89Oct 8, 25$27.00Oct 10, 25$26.32Oct 14, 25$25.42Oct 16, 25$25.79Oct 21, 25$29.89Oct 23, 25$28.20Oct 27, 25$26.73Oct 29, 25$24.77Oct 31, 25$25.01Nov 4, 25$22.74Nov 6, 25$23.15Nov 10, 25$21.65Nov 12, 25$21.87Nov 14, 25$21.72Nov 18, 25$21.92Nov 20, 25$20.60Nov 25, 25$24.69Nov 28, 25$25.33Dec 2, 25$23.37Dec 4, 25$28.91Dec 8, 25$27.10Dec 10, 25$27.40Dec 12, 25$27.36Dec 16, 25$26.76Dec 18, 25$26.17Dec 22, 25$27.92Dec 24, 25$28.14Dec 29, 25$27.84Jan 2, 26$27.14Jan 6, 26$28.34Jan 8, 26$28.00Jan 12, 26$33.69Jan 14, 26$35.41Jan 16, 26$31.22Jan 21, 26$31.12Jan 23, 26$31.56Jan 27, 26$30.70Jan 29, 26$29.29Feb 2, 26$27.92Feb 4, 26$26.95Feb 9, 26$27.28Feb 11, 26$25.99Feb 13, 26$27.92Feb 18, 26$27.56Feb 20, 26$27.59Feb 24, 26$32.29Feb 26, 26$28.92Mar 2, 26$28.69Mar 4, 26$27.44Mar 6, 26$26.54Mar 10, 26$26.08Mar 12, 26$25.59Mar 17, 26$25.83Mar 19, 26$25.17Mar 23, 26$25.17Mar 25, 26$23.12Mar 27, 26$22.19Mar 31, 26$23.83Apr 2, 26$24.66Apr 7, 26$24.49Apr 9, 26$26.33Apr 13, 26$30.18Apr 15, 26$30.68Apr 17, 26$31.39Apr 22, 26$31.69Apr 24, 26$27.11Apr 28, 26$30.56Apr 30, 26$30.33May 4, 26$30.08May 6, 26$32.34May 8, 26$32.32May 12, 26$31.58May 14, 26$29.53May 18, 26$26.81May 20, 26$27.11May 22, 26$28.64May 28, 26$32.80Jun 1, 26$31.14Jun 3, 26$29.55Jun 5, 26$29.40Jun 9, 26$30.47Jun 11, 26$29.41Jun 15, 26$31.12Jun 17, 26$32.48Jun 22, 26$35.53Jun 24, 26$33.90Jun 26, 26$34.81Jul 2, 26$34.79
$16.0152-week range$35.53
Loading valuation history…

Fundamentals

Key fundamentals

$3.4B

Market cap

120.0%

Revenue growth (YoY)

84.0%

Gross margin

-$360M

Free cash flow (USD)

-$951.3M

Net debt

Net cash position

20.2%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2017 → 2025

FY 2017$0.00FY 2018$0.00FY 2019$18.0KFY 2020$24.0KFY 2021$51.8MFY 2022$60.9MFY 2023$377.7MFY 2024$63.5MFY 2025$139.7M
$0$139.7M

Free cash flow by year

2017 → 2025

FY 2017$-3.1MFY 2018$-33.4MFY 2019$-84.5MFY 2020$-112.1MFY 2021$-113.1MFY 2022$-26.4MFY 2023$-182.9MFY 2024$-356.2MFY 2025$-360.0M
-$3.1M-$360M

Gross margin by year

2021 → 2025

FY 2021-347.8%FY 2022-411.5%FY 2023100.0%FY 2024-478.7%FY 202584.0%
-347.8%84.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

7

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $1.7M · 10b5-1 PlanEvans John M. · Director, CEO · $1.7MJul 1, 2026Filing
  • Insider sellInsider Sell $10.0MFMR LLC · 10% Owner · $10MJun 29, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 8, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • Insider sellInsider Sell $290K · 10b5-1 PlanCiaramella Giuseppe · President · $290.3KApr 6, 2026Filing
  • Insider sellInsider Sell $146K · 10b5-1 PlanBellon Christine · Chief Legal Officer · $146.4KApr 6, 2026Filing
  • Insider sellInsider Sell $80K · 10b5-1 PlanCavanagh Bethany J · SVP, Finance and Treasurer · $79.7KApr 6, 2026Filing
  • Insider sellInsider Sell $165K · 10b5-1 PlanSimon Amy · Chief Medical Officer · $164.7KApr 6, 2026Filing
  • Insider sellInsider Sell $739K · 10b5-1 PlanEvans John M. · Director, CEO · $739.3KApr 6, 2026Filing

Questions

Frequently asked questions

What is Beam Therapeutics Inc.'s market cap?

Beam Therapeutics Inc. (BEAM) has a market capitalization of $3.4B.

What is BEAM's P/E ratio?

A meaningful P/E ratio is not available for BEAM — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is BEAM's price-to-book (P/B) ratio?

BEAM trades at 2.78 times book value per share.

Are insiders buying BEAM stock?

SEC Form 4 filings show no open-market insider buys at Beam Therapeutics Inc. in the last 90 days (7 sells).

Same arena

Related companies in Biotechnology

DNLI

Denali Therapeutics Inc.

$3.4B

KNSA

Kiniksa Pharmaceuticals, Ltd.

$3.7B

TLX

Telix Pharmaceuticals Limited

$3.2B

ACAD

ACADIA Pharmaceuticals Inc.

$3.7B

CRNX

Crinetics Pharmaceuticals, Inc.

$3.7B

VCYT

Veracyte, Inc.

$3.8B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.